Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...

PDUFA target action date of Aug. 19, 2025 - WARREN, N.J., Feb. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) announced ...

All patients in both treatment arms completed the 20-week double-blind period of the study. In the 20-week double-blind period of the study, similar proportion of patients had adverse events (AEs) in ...

Scientists discover that cancer treatment DCA may help endometriosis patients by targeting the disease's abnormal cellular metabolism ...

Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long ...

Aims Clopidogrel is the most commonly prescribed thienopyridine as part of dual anti-platelet therapy for the treatment of ...

Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory submission expected early next year. The FDA approved ranibizumab (Susvimo ...

Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company ...

We recently compiled a list of the 11 AI News and Ratings You Shouldn’t Miss. In this article, we are going to take a look at where Conduit Pharmaceuticals Inc. (NASDAQ:CDT) stands against the ...

Conduit and Sarborg complete all milestones of Phase I of their AI-driven drug development collaboration, and commence transitioning to Phase II, which will focus on developing personalized ...

Objectives To investigate the effect of the L-arginine metabolism on arthritis and inflammation-mediated bone loss ... All samples were analysed in both, hydrophilic interaction chromatography (HILIC) ...